Table 3 Clinical and biological characteristics of HBsAg-positive women (n = 96) using weighted and calibrated data (ANRS 12,356 AmBASS)
From: Hepatitis B prevention and treatment needs in women in Senegal (ANRS 12356 AmBASS survey)
Variables (% of missing data) | Adult women (> 15 years) | WCBA (15–49 years) |
|---|---|---|
(%)or median [IQR] | ||
HBsAg-positive women | N = 96 | N = 87 |
HBV DNA (IU/mL) (0.0; 0.0) | ||
Undetectable (< 26) | 62.5 | 64.6 |
26 – 1,999 | 23.8 | 21.5 |
2000 – 19,999 | 5.5 | 5.9 |
20 000 – 199,999 | 3.2 | 2.6 |
> 200 000 | 5.0 | 5.4 |
HBsAg-positive women who underwent clinical and biological examinations | N = 80 | N = 73 |
Ongoing signs of cirrhosis | ||
Oedema (0.0; 0.0) | 2.1 | 2.2 |
Ascites (0.0; 0.0) | 1.0 | 1.1 |
Icterus (0.0; 0.0) | 0.0 | 0.0 |
Family history of hepatocellular carcinoma or cirrhosis in a first degree relative (0.0; 0.0) | 9.3 | 6.4 |
HBeAg-positive (0.0; 0.0) | 8.8 | 9.4 |
HIV positive (0.0; 0.0) | 0.0 | 0.0 |
HDV positive (0.0;0.0) | 0.0 | 0.0 |
ALT(0.0)a | ||
≤ 19 | 69.4 | 68.3 |
20–38 | 28.7 | 29.6 |
≥ 39 | 1.9 | 2.1 |
AST (0.0) b | ||
< 34 | 96.1 | 95.8 |
34–67 | 3.9 | 4.2 |
≥ 68 | 0.0 | 0.0 |
Inactive chronic HBV infection (0.0) HBeAg negative and anti-HBe positive and HBV DNA < 2,000 IU/mL and ALT < ULNa | 46.9 | 45.1 |
Inactive chronic HBV infection (0.0) HBeAg negative and HBeAg negative and anti-HBe positive and HBV DNA < 2,000 IU/mL and ALT < ULN | 46.9 | 45.1 |
APRI (11.3; 11.0) c | ||
< 1 | 97.9 | 97.7 |
[1;2] | 2.1 | 2.3 |
> 2 | 0.0 | 0.0 |
Eligible for long-term treatment according to the 2015 WHO guidelines | ||
APRI > 2 (11.3; 11.0) c | 0.0 | 0.0 |
Clinical diagnosis of cirrhosis (0.0; 0.0) | 0.0 | 0.0 |
≥ 30 years old AND abnormal ALT levelsa AND HBV DNA > 20,000 IU/ml (0.0; 0.0) | 0.0 | 0.0 |
Eligible for antiviral treatment according to national recommendations | ||
ALT > 2 × ULN and HBV DNA > 20,000 IU/mL | 0.0 | 0.0 |
ALT > ULN and HBV DNA > 2,000 IU/mL and FibroScan (at least F2 fibrosis) | 0.0 | 0.0 |